{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    5,
    6,
    7,
    23,
    24,
    25,
    26,
    27,
    28
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of progression-free survival (PFS) in subjects with newly diagnosed MCL who are 65 years of age or older.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - Overall Survival",
        "text": "Evaluation of overall survival",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - CR Rate",
        "text": "Evaluation of CR rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - ORR",
        "text": "Evaluation of overall response rate (CR+ partial response [PR])",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - Patient-Reported Symptoms",
        "text": "Evaluation of patient-reported lymphoma symptoms and concerns as measured by the lymphoma (Lym) subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - MRD",
        "text": "Evaluation of minimal residual disease (MRD) negative rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Objective - Duration of Response",
        "text": "Evaluation of duration of response",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Objective - TTNT",
        "text": "Evaluation of time-to-next treatment (TTNT)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Secondary Objective - Safety",
        "text": "Evaluation of safety of ibrutinib when combined with BR",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Secondary Objective - Pharmacokinetics",
        "text": "To characterize the pharmacokinetics of ibrutinib and explore the potential relationships between ibrutinib metrics of exposure with relevant clinical, pharmacodynamic, or biomarker information",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective - PRO",
        "text": "To evaluate patient-reported outcomes (PRO) related to well-being and general health status utilizing the FACT-Lym and EuroQol (EQ-5D-5L)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective - Biomarkers",
        "text": "To explore biomarkers identified from other studies of ibrutinib in samples collected for MRD assessments",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Progression-free survival (PFS) as determined by investigators",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival",
        "text": "Overall survival",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "CR Rate",
        "text": "Complete response (CR) rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Overall Response Rate",
        "text": "Overall response rate (CR+ partial response [PR])",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "FACT-Lym Subscale",
        "text": "Lymphoma (Lym) subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_6",
        "name": "MRD Negative Rate",
        "text": "Minimal residual disease (MRD) negative rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_7",
        "name": "Duration of Response",
        "text": "Duration of response",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Time-to-next treatment",
        "text": "Time-to-next treatment (TTNT)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Safety Endpoints",
        "text": "Safety assessed by physical examinations, ECOG criteria, laboratory tests, monitoring adverse events, and concomitant medication usage",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_10",
        "name": "Pharmacokinetic Parameters",
        "text": "Model-derived plasma concentrations or metrics of exposure parameters (eg, maximum observed plasma concentration [Cmax] or area under the plasma concentration versus time curve [AUC])",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_11",
        "name": "Exploratory PRO",
        "text": "Patient-reported outcomes (PRO) related to well-being and general health status utilizing the FACT-Lym and EuroQol (EQ-5D-5L)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_12",
        "name": "Exploratory Biomarkers",
        "text": "Biomarkers identified from other studies of ibrutinib in samples collected for MRD assessments",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Discontinuation of study treatment for reasons other than progression",
            "text": "Subject discontinues treatment due to adverse events or other reasons prior to disease progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death from any cause prior to documented progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Subsequent anti-cancer therapy",
            "text": "Initiation of a new systemic anti-MCL therapy prior to documented progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ibrutinib 560 mg daily + Bendamustine and Rituximab (BR) vs Placebo + Bendamustine and Rituximab (BR)",
        "analysisPopulation": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Progression-free survival (PFS) as determined by investigators",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_2",
        "name": "Overall Survival Estimand",
        "populationSummary": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment switching/Unblinding",
            "text": "Placebo subjects unblinded and/or stopping placebo treatment following DMC recommendation",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ibrutinib 560 mg daily + BR vs Placebo + BR",
        "analysisPopulation": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Overall survival",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_3",
        "name": "Response Rate Estimand",
        "populationSummary": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population) Summary measure: Odds ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Death or progression prior to response assessment",
            "text": "Subject dies or has disease progression before a CR can be documented",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ibrutinib 560 mg daily + BR vs Placebo + BR",
        "analysisPopulation": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Complete response (CR) rate",
        "summaryMeasure": "Odds ratio"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 9,
      "exploratoryObjectives": 2,
      "totalEndpoints": 12,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of progression-free survival (PFS) in subjects with newly diagnosed MCL who are 65 years of age or older.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - Overall Survival",
        "text": "Evaluation of overall survival",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - CR Rate",
        "text": "Evaluation of CR rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - ORR",
        "text": "Evaluation of overall response rate (CR+ partial response [PR])",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - Patient-Reported Symptoms",
        "text": "Evaluation of patient-reported lymphoma symptoms and concerns as measured by the lymphoma (Lym) subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - MRD",
        "text": "Evaluation of minimal residual disease (MRD) negative rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Objective - Duration of Response",
        "text": "Evaluation of duration of response",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Objective - TTNT",
        "text": "Evaluation of time-to-next treatment (TTNT)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Secondary Objective - Safety",
        "text": "Evaluation of safety of ibrutinib when combined with BR",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Secondary Objective - Pharmacokinetics",
        "text": "To characterize the pharmacokinetics of ibrutinib and explore the potential relationships between ibrutinib metrics of exposure with relevant clinical, pharmacodynamic, or biomarker information",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective - PRO",
        "text": "To evaluate patient-reported outcomes (PRO) related to well-being and general health status utilizing the FACT-Lym and EuroQol (EQ-5D-5L)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective - Biomarkers",
        "text": "To explore biomarkers identified from other studies of ibrutinib in samples collected for MRD assessments",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Progression-free survival (PFS) as determined by investigators",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival",
        "text": "Overall survival",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "CR Rate",
        "text": "Complete response (CR) rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Overall Response Rate",
        "text": "Overall response rate (CR+ partial response [PR])",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "FACT-Lym Subscale",
        "text": "Lymphoma (Lym) subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_6",
        "name": "MRD Negative Rate",
        "text": "Minimal residual disease (MRD) negative rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_7",
        "name": "Duration of Response",
        "text": "Duration of response",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Time-to-next treatment",
        "text": "Time-to-next treatment (TTNT)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Safety Endpoints",
        "text": "Safety assessed by physical examinations, ECOG criteria, laboratory tests, monitoring adverse events, and concomitant medication usage",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_10",
        "name": "Pharmacokinetic Parameters",
        "text": "Model-derived plasma concentrations or metrics of exposure parameters (eg, maximum observed plasma concentration [Cmax] or area under the plasma concentration versus time curve [AUC])",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_11",
        "name": "Exploratory PRO",
        "text": "Patient-reported outcomes (PRO) related to well-being and general health status utilizing the FACT-Lym and EuroQol (EQ-5D-5L)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_12",
        "name": "Exploratory Biomarkers",
        "text": "Biomarkers identified from other studies of ibrutinib in samples collected for MRD assessments",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Discontinuation of study treatment for reasons other than progression",
            "text": "Subject discontinues treatment due to adverse events or other reasons prior to disease progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death from any cause prior to documented progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Subsequent anti-cancer therapy",
            "text": "Initiation of a new systemic anti-MCL therapy prior to documented progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ibrutinib 560 mg daily + Bendamustine and Rituximab (BR) vs Placebo + Bendamustine and Rituximab (BR)",
        "analysisPopulation": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Progression-free survival (PFS) as determined by investigators",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_2",
        "name": "Overall Survival Estimand",
        "populationSummary": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment switching/Unblinding",
            "text": "Placebo subjects unblinded and/or stopping placebo treatment following DMC recommendation",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ibrutinib 560 mg daily + BR vs Placebo + BR",
        "analysisPopulation": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Overall survival",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_3",
        "name": "Response Rate Estimand",
        "populationSummary": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population) Summary measure: Odds ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Death or progression prior to response assessment",
            "text": "Subject dies or has disease progression before a CR can be documented",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ibrutinib 560 mg daily + BR vs Placebo + BR",
        "analysisPopulation": "Adult patients 65 years of age or older with newly diagnosed mantle cell lymphoma (MCL) meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Complete response (CR) rate",
        "summaryMeasure": "Odds ratio"
      }
    ]
  }
}